Journal
NATURE METHODS
Volume 17, Issue 5, Pages 471-479Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41592-020-0771-6
Keywords
-
Categories
Funding
- University of California San Francisco Program for Breakthrough in Biomedical Research
- Sandler Foundation
- NIH Office of the Director Early Independence Award [DP5-OD021344]
- NIH [F32GM133127, R01GM127489]
- DARPA [HR0011-17-2-0043]
- Eotvos National Scholarship of Hungary
- Marie Skodowska-Curie Actions Individual Global Fellowship of the Horizon 2020 Research Program of the European Commission [844093]
- Joint Programming Initiative-Antimicrobial Resistance (JIP-AMR
- DARWIN project) [7044-00004B]
- Innovation Fund Denmark (Trojan Horse Project) [5157-00005B]
- Marie Curie Actions (MSCA) [844093] Funding Source: Marie Curie Actions (MSCA)
Ask authors/readers for more resources
Clustered, regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) genes, a diverse family of prokaryotic adaptive immune systems, have emerged as a biotechnological tool and therapeutic. The discovery of protein inhibitors of CRISPR-Cas systems, called anti-CRISPR (Acr) proteins, enables the development of more controllable and precise CRISPR-Cas tools. Here we discuss applications of Acr proteins for post-translational control of CRISPR-Cas systems in prokaryotic and mammalian cells, organisms and ecosystems. This Review highlights recent discoveries and applications of anti-CRISPR (Acr) proteins that enable the regulation of CRISPR-Cas technology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
